Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
暂无分享,去创建一个
M. Hirsch | V. Johnson | T. Chou | T C Chou | V A Johnson | M S Hirsch | D P Merrill | D. Merrill
[1] J. A. Martin,et al. Recent advances in the design of HIV proteinase inhibitors. , 1992, Antiviral research.
[2] W. Rozenbaum,et al. EFFECTS OF ZIDOVUDINE IN 365 CONSECUTIVE PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX , 1988, The Lancet.
[3] E. Clercq. Basic approaches to anti-retroviral treatment. , 1991 .
[4] I B Duncan,et al. Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.
[5] J S Mills,et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.
[6] Roy E. Byington,et al. Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, Disease markers.